ReviewJournal of central nervous system disease2026
Deutetrabenazine in Hyperkinetic Movement Disorders: VMAT2 Modulation From Choreiform Disorders to Hyperkinetic Dystonic Syndromes.
Review in Journal of central nervous system disease, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hyperkinetic movement disorders, including dystonia and choreiform syndromes, are pathophysiologically linked to dysregulated dopamine metabolism within the basal ganglia-thalamo-cortical (BGTC) circuitry. Mounting research highlights dopaminergic hyperactivity as a driver of aberrant signaling and motor symptoms. Vesicular monoamine transporters (VMATs) package monoamines into synaptic vesicles, yet they remain pharmacologically underexplored compared to plasma membrane transporters. Recent advances in VMAT2 inhibitors offer a promising therapeutic avenue for hyperkinetic movement disorders. As a selectivity VMAT2 inhibitor, deutetrabenazine demonstrates unique advantages in dopamine modulation due to deuterium isotope-mediated metabolic stabilization, which extends the dynamics of dopamine receptor occupancy and reduces fluctuations in plasma concentration. Clinically, deutetrabenazine has emerged as a significant therapeutic approach for hyperkinetic movement disorders, with substantial evidence supporting its efficacy in the treatment of chorea associated with Huntington's disease (HD), tardive dyskinesia (TD), and Tourette syndrome. Future research should prioritize large-scale randomized trials incorporating rigorous subgroup analyses and extended safety monitoring to assess the distinct role of deutetrabenazine in other types of hyperkinetic movement disorders. This review unpacks the workings of VMAT2 inhibitors, paying particular attention to deutetrabenazine's distinct metabolic profile, and assesses their clinical promise across the range of choreiform disorders to hyperkinetic dystonic syndromes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.